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Abstract
Background: Pelvic organ prolapse (or prolapse) is a common condition in women where the pelvic organs (bladder,
bowel or womb) descend into the vagina and cause distressing symptoms that adversely affect quality of life. Many
women will use a vaginal pessary to treat their prolapse symptoms. Clinic-based care usually consists of having a
pessary fitted in a primary or secondary care setting, and returning approximately every 6 months for healthcare
professional review and pessary change. However, it is possible that women could remove, clean and re-insert their
pessary themselves; this is called self-management. This trial aims to assess if self-management of a vaginal pessary is
associated with better quality of life for women with prolapse when compared to clinic-based care.
Methods: This is a multicentre randomised controlled trial in at least 17 UK centres. The intervention group will receive
pessary self-management teaching, a self-management information leaflet, a follow-up phone call and access to a local
telephone number for clinical support. The control group will receive the clinic-based pessary care which is standard at
their centre. Demographic and medical history data will be collected from both groups at baseline. The primary outcome
is condition-specific quality of life at 18months’ post-randomisation. Several secondary outcomes will also be assessed
using participant-completed questionnaires. Questionnaires will be administered at baseline, 6, 12 and 18months’ post-
randomisation. An economic evaluation will be carried out alongside the trial to evaluate cost-effectiveness. A process
evaluation will run parallel to the trial, the protocol for which is reported in a companion paper.
Discussion: The results of the trial will provide robust evidence of the effectiveness of pessary self-management
compared to clinic-based care in terms of improving women’s quality of life, and of its cost-effectiveness.
Trial registration: ISRCTN Registry ISRCTN62510577. Registered on June 10, 2017.
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Background and rationale {6a}
Pelvic organ prolapse affects about 40% of women over
40 years of age [1], and the number of women affected is
expected to rise [2]. Prolapse is categorised into different
stages and types and affects women of varying ages. The
distressing symptoms include a sensation of “something
coming down” in the vagina, bladder, bowel and sexual
problems and pelvic and back pain. These symptoms
impact negatively on a woman’s quality of life [3].
Women presenting with prolapse are commonly
offered conservative management (such as a vaginal
pessary or pelvic floor muscle training) or surgery.
There were over 28,000 hospital admissions in England
in 2017/2018 related to female genital prolapse
associated with approximately 42,000 bed days [4].
About 9.5% of women will undergo surgery for prolapse
in their lifetime [5]. However, surgery is not always
effective or durable with 30% of women requiring at
least one further procedure [6]. With the high re-
operation rates and the controversy surrounding surgery
and the use of mesh implants, it is timely to consider
the evidence supporting conservative options in more
detail.
Currently, women who have prolapse of all types and
stages can receive pessary treatment. Most commonly,
women who use a pessary are over 60 years of age [7]
and two thirds of women will opt to try a pessary when
offered [8]. Although previous research indicates that
the ring pessary is most commonly used in practice, a
wide range of pessaries are fitted [9]. Hospital-based care
remains the most common delivery mode for women
who have a pessary with some community-based clinics
and general practices also offering services. The most
common service model for women is to return to a
healthcare professional clinic to have their pessary re-
moved and changed [7]. Most commonly, women attend
a clinic appointment every 6 months for a pessary
change, but time between changes does vary (3–12
months) [7]. It is not clear if pessaries would be used
more often if pessary care was less reliant on follow-up
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appointments, allowing easier integration of pessary
management with a woman’s lifestyle.
The largest UK-based observational study of pessary
use reported that 86% of women successfully retaining a
pessary at 4 weeks will continue to use a pessary at
5 years [10]. However, other studies have reported much
lower continuation rates [11, 12]. Reasons for discon-
tinuation of pessary use include developing complica-
tions such as bleeding or infection, dislike of the pessary
changing procedure and inconvenience of attending ap-
pointments [13].
A UK multi-professional survey found that only 17%
of clinicians offered women the option of self-managing
their pessary [7]. This is a significant difference in prac-
tice compared with North America, where the majority
of clinicians teach women pessary self-care [14]. The on-
going Cochrane review update has so far identified no
completed trials including self-management for pessary
in any comparison. Self-management focusses on actions
that people undertake for themselves to manage their
health and illness. In order to self-manage people need
self-management support (actions taken to support
people to self-manage, e.g. by healthcare professionals).
Self-management has been shown to be effective in im-
proving health outcomes such as quality of life in other
conditions; e.g. condition-specific quality of life is im-
proved for people with Chronic Obstructive Pulmonary
Disease [15].
There is only one small (n = 88) non-randomised study
that assesses self-management of vaginal pessaries [16].
Gains from self-management were reported in this study
in that women reported higher levels of convenience,
ability to access help, support and comfort than those
having clinic management [16]. Women who were self-
managing had one clinic appointment scheduled at
2 years, compared to health care professional clinic-
based care where women attend a clinic every 4 to
6 months for pessary changes. Whilst these may be
promising findings, there is an urgent need to robustly
investigate whether pessary self-management is more
clinically and cost-effective than standard pessary care.
The TOPSY study aims to address this uncertainty to in-
form clinical practice.
Objectives {7}
The aim of the TOPSY trial is to determine the clinical
and cost-effectiveness of self-management of vaginal
pessaries to treat pelvic organ prolapse, compared to
clinic pessary care on condition-specific quality of life.
Methods
Trial design {8}
The TOPSY study includes a multicentre, parallel group,
superiority randomised controlled trial (RCT), an
internal pilot study and a nested process evaluation. The
RCT and internal pilot will be described in further detail
here, whilst the protocol for the process evaluation will
be reported in a separate companion paper and will not
be addressed further here.
The aim of the internal pilot is to ensure that the
TOPSY trial can recruit, randomise and retain sufficient
numbers of participants whilst delivering the
intervention as planned. The internal pilot will aim to
recruit 63 women across six centres (identified prior to
the commencement of the study). The primary stop-go
rules are detailed in the analysis section.
We will establish if pessary self-management is cost-
effective compared to standard clinic-based pessary care
by collecting cost and resource-use data for all partici-
pants using a combination of NHS data and participant-
completed questionnaires. This is described in more de-
tail in both the outcome section and the analysis
sections.
Study setting {9}
Healthcare providers with pessary care services (who
have granted permission for the study to take place) will
identify and recruit women (for more information on
centres involved, please see https://w3.abdn.ac.uk/hsru/
TOPSY/Public/Public/index.cshtml).
Eligibility criteria {10}
Women will be eligible for inclusion if they are aged 18
or older, use a pessary of any type/material (except those
that require more complex removal techniques such as
Shelf or Gellhorn pessaries and those that must be self-
managed such as cube pessary) and have retained the
pessary for at least 2 weeks. Women will be ineligible if
they: have limited manual dexterity that would affect
their ability to remove and replace their own pessary; are
judged by their healthcare team to have a cognitive def-
icit such that it is not possible to obtain informed con-
sent or to self-manage; or are pregnant. The self-
management teaching is only available in English; there-
fore, sufficient understanding of English language is re-
quired for participation.
Recruitment {15}
Potential participants will be identified in the following
ways:
1. Reviewing patient notes, clinic lists or caseloads to
identify women who are currently using a pessary
and could be approached;
2. At a pessary appointment when women attend for
pessary review (existing users) or are fitted with a
pessary for the first time (new users); and
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3. Women who learn about the TOPSY study
themselves (website, posters, word of mouth) and
approach their centre or the trial office (this would
be dependent on there being a TOPSY recruitment
centre local to the women).
Women who are identified as potential participants
through the mechanisms detailed above will be given a
recruitment pack which contains an introductory letter,
a participant information leaflet, an expression of
interest form and a reply paid envelope. Women
identified via patient notes, clinic lists or caseloads will
have the recruitment pack posted to them by the “local
TOPSY clinical team”. Women identified at their
pessary appointment will be given the same recruitment
pack in clinic. If time restraints in clinic mean that the
local TOPSY clinical team are unable to fully discuss the
study with the woman after giving out a pack, a follow-
up call with the woman from a member of the research
team at the centre delegated to do so can be arranged
for an agreed time.
Once women have had enough time to make their
decision, they can return the expression of interest form
by post or in person to the local TOPSY clinical team to
indicate if they are interested in participating or not. On
receiving a positive expression of interest form, a
member of the local TOPSY clinical team will discuss
the study further with the woman and screen her for
eligibility.
In addition, for women who are new pessary users
(used a pessary for 3 months or less), eligibility screening
will be finalised by a telephone call to assess if the
pessary has been retained for at least 2 weeks. If the
pessary has not been retained for 2 weeks, standard
centre protocol would be followed for further pessary
care. If women indicate that they remain interested in
participating in TOPSY, eligibility will be reassessed
once standard centre protocol is followed and the
pessary has been retained for 2 weeks.
Who will take informed consent? {26a}
If a woman is eligible and willing to take part, she will
be asked to come to a baseline clinic appointment to
provide written, informed consent for randomisation
and completion of baseline questionnaires and
demographic data (see “Outcomes” section for more
information).
Informed consent procedures will ensure that women
understand participation is voluntary and that
participants can withdraw from all or any part of the
research at any time without affecting their participation
in other parts of the study, or their healthcare. Women
may choose to withdraw from the treatment aspect of
the study, but continue to provide data, for example by
completing questionnaires. Where women cannot, or
choose not to, continue to self-manage, this will be re-
corded and women, where willing to do so, will continue
to complete questionnaires. If withdrawal occurs, the
primary reason for withdrawal will be documented in
the participant’s case report form (CRF), if possible.
After full withdrawal, no further data will be collected
from the participant but data collected up to that point
will be analysed.
If a participant is randomised and then withdraws
prior to any trial intervention being undertaken, for trial
purposes the woman will continue to be included within
her original allocated group, and if data are available, in
the intention to treat (ITT) analysis. If women in the
self-management group cross over to clinic-based care
during the trial, they will follow the trial clinic-based
care group protocol. A change of status form will be
completed in all of the above examples to indicate the
nature of the change of status and to monitor participant
attrition rates. The Data Monitoring and Ethics Com-
mittee (DMEC) will review change of status information
at an appropriately agreed frequency.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
The main trial consent asks participants if they would be
willing to be contacted about the interviews (for the
process evaluation part of TOPSY) or if they would be
willing to have their teaching session or their 2-week
follow-up call audio-recorded. They are also asked if
they would be happy to be contacted in the future about
research. Participants can say no to any of these ques-
tions and still take part in the TOPSY study.
Assignment of interventions
The trial is supported by The Centre for Healthcare
Randomised Trials (CHaRT; a fully registered UK CRN
clinical trials unit in the Health Services Research Unit,
University of Aberdeen). CHaRT will develop the data
management system, a remote randomisation system,
and will be responsible for ensuring the reliability of
data at data-lock and compliance with the Research
Governance Framework and Good Clinical Practice.
Sequence generation {16a}
Randomisation will be minimised (naïve minimisation)
by age (< 65/≥ 65 years), pessary user type (new user/
existing user) and centre.
Concealment mechanism {16b}
This randomisation application will be available as an
internet-based service, located within the TOPSY data
management system.
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Implementation {16c}
A trained and delegated member of the local TOPSY
research team will randomise women at each centre by
accessing the data management system and entering the
required information, which will generate the group
allocation and display it on screen/and relay this
information in an email.
Who will be blinded? {17a}
The trial group to which women are allocated cannot be
masked from the participants or the centre staff after
randomisation has occurred. Blinding is therefore not
possible.
Procedure for unblinding if needed {17b}
Unblinding is not applicable.
Intervention description {11a}
Self-management interventions are highly heterogeneous
[14, 16–18], making identification of the effective
component parts of an intervention difficult. However,
based on evidence drawn from large scale self-
management programmes, three tasks need to be
achieved in order for individuals to self-manage [17]:
medical management of the condition, role management
and emotional management.
Pessary self-management
To support a woman to achieve the three tasks needed
for self-management, the intervention will be directed at
three levels:
 At a service level to facilitate a supportive culture
for a self-management treatment pathway.
 At a professional level to ensure that staff have the
self-management teaching and support skills.
 At an individual woman level to ensure women can
achieve the necessary tasks to self-manage.
Supporting delivery of self-management at service and
professional levels
At a service level, the TOPSY training team (a clinical
co-applicant and the trial manager) will visit all trial cen-
tres and will discuss with staff the trial processes and the
self-management protocol.
A training manual for those staff teaching women self-
management has been developed: with Patient and Public
Involvement (PPI) input (including a focus group with
women from the Royal College of Obstetricians and
Gynaecologists (RCOG) PPI group, Women’s Voices);
through discussion with our clinical co-applicants (which
includes urogynaecologists from across the UK, nurses
and a physiotherapist); using International Consultation
on Incontinence recommendations [19]; using best prac-
tice guidance from the self-management literature.
Intervention components delivered to individual women
Women allocated to self-management will receive: a
self-management teaching appointment, a self-
management information leaflet, a 2-week follow-up
telephone call, and a telephone helpline number/email
address for their local clinical site.
Each woman in the self-management group will re-
ceive a 30min, one-to-one self-management teaching
appointment with an intervention healthcare profes-
sional (HCP) who has been trained in the pessary self-
management intervention by the TOPSY training team.
The intervention HCP is most likely to be a specialist
nurse or physiotherapist, but may also be a urogynaecol-
ogist or general practitioner (GP). They have to be in-
volved in pessary management as part of their clinical
role to be eligible to teach women the intervention for
the TOPSY study. The teaching appointment should
take place within 4 weeks of the randomisation date.
The self-management training manual specifies in detail
the key components of the self-management interven-
tion, facilitating standardisation of the self-management
intervention across the centres. The key components as
laid out in the training manual will be used by the inter-
vention HCP when teaching women within the teaching
appointment.
During the self-management teaching appointment,
women will be given a self-management information
leaflet containing written information on pessary self-
management. The leaflet was initially developed as part
of a previous non-randomised study [16] and is based on
the viewpoints of, and feedback from, PPI representa-
tives. The leaflet has undergone further development,
drawing on the expertise of TOPSY PPI representatives,
Women’s Voices (RCOG) focus group members and
clinical co-applicants. The leaflet includes diagrams of
various pessary types and pelvic floor anatomy, informa-
tion about common complications and what to do if
these are experienced. The same leaflet will be used
across all centres.
Strategies to improve adherence to interventions {11c}
During the self-management teaching session and rein-
forced in the self-management leaflet, women in the
self-management group will be asked to remove, clean
and re-insert their pessary at least once in the 2 weeks
following the self-management teaching appointment.
The woman will be telephoned 2 weeks after the ap-
pointment and asked if she has been successful in re-
moving, cleaning and re-inserting her pessary. They will
discuss any difficulties experienced. If the woman has
not changed the pessary, the HCP will ask her to do so
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over the next week, and will call her again to check if
this has been achieved. Where a woman has experienced
difficulty that requires assessment by the HCP or where
the woman has not changed the pessary by the time of
the second phone call, she will be offered a second self-
management teaching appointment. If, after this second
appointment, the woman is unable to self-manage or
does not wish to do so, she will be given the choice to
transfer to clinic-based pessary care. All information on
these interactions with women and any subsequent
crossovers will be recorded in the study-specific CRF.
Once it is clear that the woman has been able to remove
and re-insert the pessary at least once, she will be asked
to remove and re-insert the pessary at least once every
6 months. This information will be given as part of the
self-management teaching appointment and is written
into the information leaflet.
Women in the self-management group will receive a
local telephone number and an email address to use to
make contact with the intervention HCP at their centre
if they experience any pessary problems or have ques-
tions (numbers of contacts received and details of rea-
sons for calls will be recorded by the centre).
Women with PVC pessaries in both groups will
receive a new PVC pessary every 6 months (women in
the self-management group will either receive their new
pessary by post or by picking up a prescription or some
centres may give 2 extra pessaries at the baseline visit).
Women in the self-management group with silicone
pessaries, which are more durable, will only have the
pessary changed by request if required (e.g. if the pessary
becomes damaged) and women with silicone pessaries in
the clinic-based care group will have the pessaries chan-
ged as per local centre protocol. Self-management leaf-
lets will include information about what women need to
do if they require a new pessary.
Women in both trial groups will be asked to complete
questionnaires every 6 months which will include
questions regarding their patterns of pessary removal
and re-insertion. At 18 months after randomisation,
women in both groups will attend a clinic appointment
which will include an examination of vaginal tissues,
comparable to that carried out routinely in clinic-based
pessary care (see below).
Provisions for post-trial care {30}
Care will continue as normal for women in the standard
care group. Local centres can provide training on self-
management if this service is currently offered. For
women who have been in the self-management group, it
will be up to them and each local centre how often
women are seen back in clinic. We will capture this infor-
mation in the end of study case report form.
Criteria for discontinuing or modifying allocated
interventions {11b}
There are no special criteria for discontinuing or
modifying allocated interventions. Participants may
choose to revert back to standard care themselves for
any reason or may choose to stop using a pessary.
Relevant concomitant care permitted or prohibited
during the trial {11d}
No special provisions.
Explanation for the choice of comparators {6b}—clinic-
based pessary care
Women will receive a clinic appointment for their
pessary care according to the local management
pathway. Content of appointments will follow local
protocol which usually includes vaginal examination to
remove the pessary, inspection of the vaginal tissues and
insertion of a new pessary. Data on frequency of
appointments and of pessary changes at appointments
will be recorded in the CRF. Healthcare professionals
who deliver standard pessary care at each centre will be
interviewed as part of the process evaluation allowing
variation in standard pessary care to be described.
Recruitment and retention of study centres
Each collaborating centre will appoint a local intervention
HCP as part of the local TOPSY research team who will
be trained on the self-management intervention and who
will keep regular contact with the local PI, with notifica-
tion of any problems or unexpected developments. Each
centre will have a centre initiation visit to ensure all study
processes are in place before recruitment commences.
The TOPSY Study Office will set up regular centre “for-
ums” for all centres to “phone in” and discuss any prob-
lems experienced and share learning. Updates will be
provided via quarterly newsletters. Centres having specific
problems with recruitment and/or retention will be of-
fered additional support either remotely or by an add-
itional centre visit.
Outcomes {12}
Plans for assessment and collection of outcomes {18a}
Throughout the TOPSY study, data will be gathered
from the women in the trial, and the TOPSY clinical
research staff at each study centre. The outcome
measures collected are described in the sections below
and in Table 1.
Primary outcome
The primary outcome, condition-specific quality of life at
18months post-randomisation, will be measured via
participant-completed questionnaires using the PFIQ-7.
The PFIQ-7 [20] is a reliable, valid and responsive short
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form of the Pelvic Floor Impact Questionnaire (PFIQ)
which measures condition-specific quality of life in
women with pelvic floor disorders including urinary in-
continence, prolapse and faecal incontinence. There are
three subscales: urinary (UIQ-7), colorectal-anal (CRAIQ-
7) and pelvic organ prolapse (POPIQ-7), with each sub-
score ranging from 0 to 100 and a total score ranging from
0 to 300. Data will be collected at each time-point to allow
repeated measures analysis of the PFIQ-7 scores.
Secondary outcome measures
Several secondary outcomes will be collected as described
below. Frequency of collection for each outcome is shown
in Table 1.
Participants’ health-related quality of life will be mea-
sured by Euroqol (EQ-5D-5L) complementing the primary
outcome measure of condition-specific quality of life, and
also providing data for the analysis of cost-effectiveness
(see section “Data collection for economic evaluation” for
more information).
The severity of prolapse-related symptoms will be mea-
sured by PFDI-20. This was developed and validated in
parallel with the PFIQ-7 [20]. It contains 20 questions
about the presence of bladder, bowel and pelvic symp-
toms, and how bothersome these are.
Women’s sexual symptoms will be assessed by The
Pelvic Organ Prolapse/Urinary Incontinence Sexual
Questionnaire (PISQ-IR) [21].
A woman’s general self-efficacy (as a moderator of
quality of life) will be measured by the General Self-
Efficacy scale (GSE) [22].
Pessary complications
A new pessary questionnaire developed for TOPSY
(with 15 possible complications of pessary use),
developed based on the literature, PPI opinion and the
team’s experiences in the pilot study, will be used to
record women’s pessary complications (e.g. discharge,
odour, pain, discomfort, bleeding). The questionnaire
record will be used to collect the secondary outcome
measure of pessary-related complications to report on
the impact and safety of the trial interventions.
Pessary use
A new questionnaire (including eight questions) developed
based on the literature, PPI consultation and the team’s
experiences in the pilot study will be used to collect data on
the pattern of a woman’s pessary use, including pessary
continuation and perceived acceptability and benefit. This
will include questions that ask women the following:
whether or not they are still using a pessary as treatment
for prolapse; when they last removed and re-inserted their
pessary; reasons for pessary removal; interference of the
pessary with everyday life; and if they find the pessary an
Table 1 Item 13 in the SPIRIT checklist
(a) All women will complete their 6-, 12- and 18-month follow-up
questionnaires via a paper questionnaire booklet or via a link to complete
online (participant preference). Only women in the clinic-based care group will
attend a clinic appointment as per the centre’s standard care
(b) Women in the clinic-based care group will have vaginal tissues assessed at
each clinic appointment as per standard practice. Women in the self-
management group will have their vaginal tissues assessed at baseline and
18-month appointments
Hagen et al. Trials          (2020) 21:837 Page 7 of 13
acceptable treatment. Also included is a question adapted
from the Patient Global Impression of Improvement (PGI-
I) which will be used to assess perceived benefit of the pes-
sary care regimens being evaluated. The PGI-I is a single-
item tool asking the individual to rate the change in their
condition since having treatment, which has been validated
for urogenital prolapse [23, 24]. An amended version asking
women to describe how they feel about their pessary care
since taking part in the study will be used, with response
options ranging from very much better to very much worse.
Patterns of pessary use are used to measure impact, adher-
ence and acceptability of the trial interventions.
Pessary confidence (to measure pessary-specific self-
efficacy)
No suitable condition-specific measure exists; thus,
questions relating to pessary self-efficacy were developed
based on the guidance from Bandura [25]. These six
questions have been developed with PPI representatives,
PPI input, statistical input and clinical team members.
We will use both the generic validated measure of self-
efficacy (GSE) and the responses to the newly developed
pessary-specific self-efficacy questions to measure self-
efficacy and help us understand the influence it has as a
moderating factor on quality of life.
Uptake of additional treatment for prolapse
As an indicator of intervention effectiveness, the uptake of
other treatment for prolapse since the start of the study,
or treatment awaited, will be recorded in participant
questionnaires (e.g. surgery, pelvic floor muscle training,
oestrogen, lifestyle advice). Women’s access to
professional pessary-related support since starting the
study will also be recorded (e.g. telephone support, hos-
pital appointment, GP appointment). These data will be
collected at all trial time-points to improve data quality as
they rely on women recalling events occurring over a
period of some months. Additional treatment will be de-
scribed as part of the main trial findings to assist in under-
standing adherence and level of support women need, as
well as being used as part of the cost-effectiveness
analysis.
Uptake of telephone support related to pessary use
Using a Telephone Support Log Form, we will ask the
intervention HCP who receives women’s calls to record
frequency and details of all calls received to the telephone
support line. There will be a question in the pessary
complication questionnaire that asks all women if they
required telephone support as some women in the clinic-
based care group may also telephone for support from
their local team. This will help understanding of adher-
ence, effectiveness and level of support relating to the trial
interventions.
Adherence to randomised protocol
Adherence to the self-management or clinic-based care
protocol will be monitored throughout the trial. Moni-
toring will be via multiple data sources: questions within
the pessary use questionnaire, telephone support con-
tacts and health records. It will include crossover to the
other trial group (i.e. self-managing women opting to
move to clinic-based care). Clinic-based care women will
not have access to the trial self-management teaching
and support intervention, but they may choose to re-
move and replace their pessary at home and this will be
recorded in the pessary use questionnaire.
Health of vaginal tissues
At baseline and 18months, women will have a vaginal
examination undertaken at the clinic by a healthcare
professional to assess the health of the vaginal tissues
and identify problems associated with pessary use, for
example, tissue granulation or ulceration. Any findings
will be recorded in the CRFs.
Biological specimens {33}
No biological specimens are collected as part of TOPSY.
Data collection for economic evaluation
An economic evaluation will be conducted alongside the
main trial. For both groups, the EQ-5D-5L will be com-
pleted as part of the participant questionnaires at baseline,
6, 12 and 18months (http://www.euroqol.org/) to allow
estimation of QALYs for a cost-utility analysis. In both
trial arms, resource use will be captured by a combination
of health data and participant-completed questionnaires.
Questionnaires will be completed at 6, 12 and 18months.
Resource use related to appointments will be captured
from patient case record forms at each appointment.
Overall costs will be estimated by multiplying resource
use by unit costs obtained from the appropriate sources
including trial-specific costs, NHS reference costs, Unit
costs of Health and Social Care and the British National
Formulary (BNF).
Plans to promote participant retention and complete
follow-up {18b}
Active measures to minimise loss to follow-up of women
include:
1. Recording at the outset women’s email addresses
and mobile phone numbers, their preferred method
of contact (for follow-up contact) and their pre-
ferred method of completion of questionnaires.
Questionnaires can be completed online (via an
email link) or in paper format and returned by post.
2. Participants who do not return their questionnaires
within 3 weeks will be sent up to three reminders
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using a variety of methods (post/email/ text
message dependent on participants preferred
method). The third reminder will be by telephone
where the researchers will aim to gather, at a
minimum, the primary outcome data during the
call.
3. Response rates to the self-reported questionnaires
will be monitored to ensure they remain above 80%
(the level assumed in the sample size calculation). If
response rates are seen to drop, the team will dis-
cuss appropriate actions with the project manage-
ment group. Relevant action may include phone
calls at different times of day or asking women to
only complete the primary outcome measure.
Data management {19}
All participants are given an individual study ID which
will be used on all case report forms for that participant.
Data will be entered into the secure database by the data
coordinator based at the TOPSY study office at Glasgow
Caledonian University. Local Centre staff will only enter
the information required for randomisation (consent
and eligibility information).
Sample size {14}
The aim is to recruit a sample size sufficient to detect a
20-point difference in the PFIQ-7 score, which we con-
sider to represent an important clinical difference (the po-
tential range of the PFIQ-7 is 0 to 300). A sample size of
330 women (165 per group) is required to provide 90%
power to detect a difference of 20 points in the PFIQ-7
score at 18months, assuming a standard deviation of 50
based on previous studies [26, 27], two-sided alpha of 0.05
and 20% loss to follow-up. In order to detect this standar-
dised effect size of 0.4 SDs (20/50 points), 132 women will
need to be recruited per group, or 165 per group to allow
for dropout.
Stopping guidelines {21b}
Data from the internal pilot will be examined and the
following stop-go rules will apply [28, 29].
 If the overall recruitment rate across pilot centres is
75% or more of the total expected recruitment (i.e.
at least 47 out of 63), the trial will continue.
 If the recruitment rate is 50–75% (31–46 women),
the trial will continue with a clear plan to overcome
barriers to recruitment that is based on review of
screening logs at centres, the trial protocol and the
qualitative recruitment data (process evaluation).
 If the recruitment rate is 25–50% (16–30 women),
screening logs, the protocol and the qualitative
recruitment data (process evaluation) will be
reviewed and the trial will only continue after
discussion with and approval by NIHR HTA and
with a clear plan to recruit within more centres and
address the recruitment shortfall.
 Should recruitment be < 25% (15 women or less), we
will enter into discussions with the funder but it is
not expected the trial will progress. The decision to
stop the trial will be made by the TSC and the
funder.
In addition, we have set the following secondary
targets:
 40% of eligible new and 20% of eligible existing
pessary users invited agree to randomisation;
 60% of the pilot self-management women (n = 19 of
31 women randomised to self-management) still self-
managing at 2-week telephone follow-up (i.e. have re-
moved and re-inserted their pessary at least once).
Statistical methods for primary and secondary outcomes
{20a}
A single main analysis will be performed at the end of the
trial when 18-month follow-up has been completed. The
independent DMEC will review confidential interim ana-
lyses of accumulating data at its discretion but at least an-
nually. All analyses will be conducted according to a pre-
specified statistical analysis plan.
All outcomes will be described with the appropriate
descriptive statistics: mean and SD for continuous
outcomes (or medians and interquartile range for skewed
data), and counts and percentages for dichotomous and
categorical outcomes.
The main effectiveness analysis will be based on the ITT
principle. The analysis of the primary outcome will
estimate the mean difference (with 95% confidence
intervals) in the PFIQ-7 score at 18months between the
self-management and standard care groups using a mixed
effects repeated measures model (which assumes incom-
plete outcome data to be missing at random). The model
will incorporate age (< 65/≥ 65) and pessary user type
(new/existing) and baseline PFIQ-7 as fixed effects and
participant and recruitment centre as random effects. Stat-
istical significance will be at the 5% level.
Secondary outcomes will be analysed using an
appropriate generalised linear model, for example binary
logistic regression for dichotomous outcomes such as
discontinuation with pessary (Y/N), and ordinal logistic
regression for ordered categorical outcomes such as
women’s global impression of improvement (PGI-I). All
models will be adjusted for minimisation covariates (age,
pessary user type and centre) and baseline score (where
applicable).
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Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
The missing at random assumption for primary outcome
data will be assessed further in sensitivity analyses.
Treatment effects will be estimated under varying
assumptions of data being missing not at random using
pattern-mixture models. A complete case analysis will
also be conducted.
Given the potential for crossover, we will conduct a
secondary analysis of compliers to estimate the effect of
receiving the self-management intervention, using com-
plier average causal effect (CACE) estimators. The
CACE analysis will take a maximum likelihood ap-
proach, which can assume incomplete data to be missing
at random, and can be adjusted for covariates. This ana-
lysis will provide unbiased effect estimates of receiving
the self-management intervention, which will comple-
ment the ITT effect estimates.
Methods for additional analyses {20b}
Subgroup analyses will be carried out within the
following groups: age (< 65/≥ 65 years), hysterectomy (Y/
N) and type of pessary user (new versus existing).
Stricter levels of statistical significance (2P < 0.01) will be
sought, reflecting the exploratory nature of these
analyses. Heterogeneity of treatment effects amongst
subgroups will be tested for using the appropriate
subgroup by treatment group interactions [30].
Economic analysis
Cost-effectiveness analysis
The primary analysis will be undertaken at 18 months
from an NHS perspective. All costs and outcomes
beyond 1 year will be discounted at 3.5% [31]. A broader
perspective including women’s personal expenditures
will be included in a sensitivity analysis. Incremental
cost-effectiveness ratios (ICERs) will be computed by
comparing the costs and outcomes of the self-
management and clinic-based care trial groups. The dif-
ference in effectiveness will be expressed in terms of the
change in score on the primary outcome measure PFIQ-
7 (cost-effectiveness analysis). The difference in utility
between the two groups will be expressed in terms of
QALYs calculated using the UK value set for patient-
reported EQ-5D-5L data [32]. This will be used in a
cost-utility analysis to calculate the incremental cost per
QALY gained.
Longer-term decision modelling
To examine the costs and outcomes of self-management
compared to clinic-based care beyond the trial period, a
decision analytic model will be developed. This will
involve extrapolating data from the trial period and sup-
plementing with additional data from the literature and
other data sources as required. A 5-year time frame will
be used and the care pathway over this period will be
mapped out. We will incorporate data on the number of
women who would want to self-manage, continued
pessary use, continuation rates for self-management,
complications and adverse events, conversion to surgery
rates for both self-management and clinic-based care,
health outcomes (prolapse and general quality of life
outcomes), expenditure attending follow-up appoint-
ments in both groups, expenditure on replacement
pessaries in both groups (type-dependent) and other
(potentially rare) outcomes of interest that we would
unlikely to see during the 18-month trial period (e.g.
fistula). Using this model, we will perform cost-
effectiveness analyses by synthesising trial data and data
from other sources. Robustness of the results will be
assessed through probabilistic sensitivity analyses. This
will allow us to examine longer-term outcomes and
cost-effectiveness under the presence of uncertainty.
Interim analyses {21b}
A single main analysis will be performed at the end of
the trial when the 18-month follow-up has been com-
pleted. The DMEC will review confidential interim ana-
lysis of accumulation data at its discretion but at least
annually.
Composition of the coordinating centre and trial steering
committee {5d} and composition of the data monitoring
committee, its role and reporting structure {21a}
An independent trial steering committee (TSC) will
review the study on behalf of the sponsor and the funder.
A separate and independent data monitoring and ethics
committee (DMEC) will be convened. Both committees
will have an independent chair. The DMEC will report to
the TSC. During the period of recruitment to the trial, the
DMEC will review a report on accumulating safety data at
each meeting, together with other analyses that the
committee may request.
The trial will also be overseen by a project
management group (PMG; consisting of the grant
applicants, the trial staff and 3 public and patient
representatives).
Frequency and plans for auditing trial conduct {23}
The TSC and DMEC will meet every 6months during
recruitment and then annually. The PMG will meet (via
teleconference) every 6 to 8 weeks. The TOPSY study
office will monitor the quality of the data returned by
the study centres and action accordingly.
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Adverse event reporting and harms {22}
All women in the TOPSY study have had a vaginal pessary
inserted. As a foreign body placed in the vagina, this is
recognised as a potential cause of specific symptoms, e.g.
bleeding and vaginal ulceration/erosion. Expected events
arising from pessary treatment are noted below and thus
will NOT be collected as adverse events but will be
recorded:
 Granulation of vaginal tissue
 Involuntary expulsion of pessary
 Vaginal smell
 Vaginal discharge
 Bleeding during pessary change.
The questionnaires completed at the 6-, 12- and
18-month follow-up include a pessary complication
questionnaire where women will indicate any compli-
cations they have experienced.
In the clinic-based care group, the local clinical
TOPSY research team will ask about the occurrence
of AEs/SAEs at every pessary follow-up appointment.
Open-ended and non-leading verbal questioning of
the participant will be used to enquire about AE/SAE
occurrence. Participants will also be asked if they
have been admitted to hospital, had any accidents,
used any new medicines or changed medication regi-
mens. If there is any doubt as to whether a clinical
observation is an AE, the event should be recorded.
Women in the self-management group are asked dur-
ing the teaching appointment and advised in the in-
formation leaflet to call the telephone helpline if they
experience any of the symptoms that may be indica-
tive of an SAE/AE. The pessary complication ques-
tionnaire completed by all women at all time-points
will also capture any adverse events experienced.
We have adhered to the new structured study protocol
template which includes all SPIRIT headings and item
identifiers.
Dissemination plans {31a}
In addition to the main funding report, journal
publications and conference presentations, we will make
the training manuals and materials available online and
training days will be arranged. Where possible our
relevant patient and clinical representatives will be part
of the dissemination activities (training days,
presentations).
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Funders, sponsors and National Health Service Research
& Development Offices will be notified routinely and
appropriate approvals gained and communicated as
required by them and by the trial sponsor.
Plans to give access to the full protocol, participant level
data and statistical code {31c}
The full Trial Protocol is available on the funder’s website
(https://www.journalslibrary.nihr.ac.uk/programmes/hta/16
8201/#/). A second paper detailing the process evaluation
of TOPSY has been submitted to TRIALS as a companion
paper. Anyone interested in other data or documentation
should contact the corresponding author.
Discussion
Due to the anticipated rise in the prevalence of prolapse
with an ageing population, there will be an anticipated
increasing demand on pessary management services
which will have increased cost implications across all
NHS trusts. Some pessary management services in
different regions across the UK offer women the option
to learn how to self-manage their own pessaries but
there is limited evidence to support this practice. There
is currently no “gold standard” on how self-management
is taught to women, no evidence on the support struc-
tures that should be available to support self-managing
women or on how often women should be seen in clinic
if self-managing. The TOPSY study is therefore crucial
to evaluate the effectiveness of self-management on a
woman’s quality of life and the potential impact on
current and future NHS workload. TOPSY is the first
trial of self-management in pelvic floor dysfunction.
Previous pessary trials, where women are randomised
prior to pessary fitting, have an attrition rate of
approximately 40% [26, 33, 34]. A particular strength of
the TOPSY trial design is to ensure that women have
managed to retain their pessary for at least 2 weeks
before they are eligible to be randomised. It is
anticipated that having less attrition will support a true
test of whether or not self-management is more effective
in improving women’s quality of life than clinic-based
care.
If the TOPSY study concludes self-management has a
positive effect on a women’s quality of life in regard to
management of pelvic organ prolapse and has cost bene-
fits to the NHS, it is hoped that the intervention package
(including the training manuals and literature developed
for TOPSY) will be rolled out and implemented across
the UK.
Confidentiality {27}
All investigators and study centre staff involved in this
study will comply with the requirements of the General
Data Protection Regulations (GDPR) and the Data
Protection Act 2018 in regard to the collection, storage,
processing and disclosure of personal information.
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Data collected during the course of the research is
kept strictly confidential and accessed only by members
of the research team and may be looked at by
individuals from the sponsor organisation or NHS sites
where it is relevant to the participant taking part in this
trial.
Trial status and internal pilot
The first participant was randomised on the 16th of May
2018. All six pilot centres were recruiting by June 2018,
and 72 participants were recruited by the end of the
pilot phase on 16 November 2018. The principal stop/go
criterion was therefore met and the trial continued.
The secondary target of at least 60% of women self-
managing at 2 weeks was also met with 83% of those
randomised to self-management still self-managing at
2 weeks. The target of 20% of existing users was
exceeded with 22% of eligible existing users randomised.
The target of 40% of new users was not met with only
28% of eligible new users randomised. This lower than
the anticipated figure led to a re-profiling of recruitment.
As a consequence, the number of centres was increased,
currently 21 centres are open to recruitment across the
UK, and the recruitment period was extended until
January 2020. Data collection will continue until 2021.
As part of the process evaluation, data was gathered
about participant recruitment processes, the findings of
these elements of the pilot study will be submitted for
publication imminently.
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